Insulin signaling in the arterial wall

American Journal of Cardiology

Volumn 84, Issue 1 A, 1999, Pages 21-24

  Hsueh, Willa A ^a   Law, Ronald E ^a  

^a Division of Endocrinology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; GROWTH FACTOR; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN KINASE; THROMBIN; TRANSCRIPTION FACTOR;

ARTERY WALL; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CELL AGGREGATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; ENDOTHELIUM CELL; FIBRINOLYSIS; HIGH RISK POPULATION; INFLAMMATORY CELL; INSULIN RESISTANCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE ADHESION;

EID: 0033536236     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00353-7     Document Type: Conference Paper

References (35)

1. Hsueh W.A., Quinones M.J., Creager M.A. Endothelium in insulin resistance and diabetes. Diabetes Rev. 5:1997;343-352.
2. Kornowski R., Mintz G.S., Kent K.M., Pichard A.D., Satler L.F., Bucher T.A., Hong M.K., Popma J.J., Leon M.B. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia a serial intravascular ultrasound study . Circulation. 95:1997;1366-1369.
3. Schwartz S.M., deBlois D., O'Brien E.R.M. The intima soil for atherosclerosis and restenosis . Circ Res. 77:1995;445-465.
4. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 326:1992;242-250.
5. Plutzky J. Atherosclerotic plaque rupture emerging insights and opportunities . Am J Cardiol. 84:1999;15J-20J.
6. Baron A.D. Vascular reactivity. Am J Cardiol. 84:1999;25J-27J.
7. Garg U.C., Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 83:1989;1774-1777.
8. Sarkar R., Meinberg E.G., Stanley J.C., Gordon D., Webb R.C. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res. 78:1996;225-230.
9. von der Leyen H.E., Gibbons G.H., Morishita R., Lewis N.P., Zhang L., Nakajima M., Kaneda Y., Cooke J.P., Dzau V. Gene therapy inhibiting neointimal vascular lesion in vivo transfer of endothelial cell nitric oxide synthase gene . Proc Natl Acad Sci USA. 92:1995;1137-1141.
10. Marks D.S., Vita J.A., Folts J.D., Keaney J.F. Jr, Welch G.N., Loscalzo J. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest. 96:1995;2630-2638.
11. De Caterina R., Libby P., Peng H.-B., Thannickal V.J., Rajavashisth T.B., Gimbrone M.A. Jr, Shin W.S., Liao J.K. Nitric oxide decreases cytokine-induced endothelial activation Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines . J Clin Invest. 96:1995;60-68.
12. Zeiher A.M., Fisslthaler B., Schray-Utz B., Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res. 76:1995;980-986.
13. Peng H.-B., Libby P., Liao J.K. Induction and stabilization of IκBα by nitric oxide mediates inhibition of NF-κB. J Biol Chem. 270:1995;14214-14219.
14. Loscalzo J. Antiplatelet and antithrombotic effects of organic nitrates. Am J Cardiol. 70:(suppl):1992;18B-22B.
15. Radomski M.W., Moncada S. The biological and pharmacological role of nitric oxide in platelet function. Adv Exp Med Biol. 344:1993;251-264.
16. Banskota N.K., Taub R., Zellner K., King G.L. Insulin, insulin-like growth factor I and platelet-derived growth factor interact additively in the induction of the protooncogene c-myc and cellular proliferation in cultured bovine aortic smooth muscle cells. Mol Endocrinol. 3:1989;1183-1190.
17. Xi X.-P., Graf K., Goetze S., Hsueh W.A., Law R.E. Inhibition of MAP kinase blocks insulin-mediated DNA synthesis and transcriptional activation of c-fos by Elk-1 in vascular smooth muscle cells. FEBS Lett. 417:1997;283-286.
18. Anderson P.W., Zhang X.Y., Tian J., Correale J.D., Xi X.P., Yang D., Graf K., Law R.E., Hsueh W.A. Insulin and angiotensin II are additive in stimulating TGF-β1 and matrix mRNAs in mesangial cells. Kidney Int. 50:1996;745-753.
19. Tamaroglio T.A., Lo C.S. Regulation of fibronectin by insulin-like growth factor-1 in cultured rat thoracic aortic smooth muscle cells and glomerular mesangial cells. Exp Cell Res. 215:1994;338-346.
20. Goetze S., Xi X.-P., Kawano H., Kawano H., Fleck E., Hsueh W.A., Law R.E. PPARγ-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharm. 33:1999;798-806.
21. Goetze S., Xi X.P., Kawano H., Kawano H., Fleck E., Hsueh W.A., Law R.E. TNF-α-induced migration of vascular smooth muscle cells is MAPK dependent. Hypertension. 33:1999;183-189.
22. Graf K., Xi X.-P., Yang D., Fleck E., Hsueh W.A., Law R.E. Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension. 29:1997;334-339.
23. Graf K., Xi X.-P., Hsueh W.A., Law R.E. Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells. FEBS Lett. 400:1997;119-121.
24. Xi X.-P., Graf K., Goetze S., Fleck E., Hsueh W.A., Law R.E. Central role of the MAPK pathway in Ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells. Atheroscler Thromb Vasc Biol. 19:1999;73-82.
25. Klemke R.L., Cai S., Giannini A.L., Gallagher P.J., de Lanerolle P., Cheresh D.A. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol. 137:1997;481-492.
26. Laakso M., Edelman S.V., Brechtel G., Baron A.D. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese men a novel mechanism for insulin resistance . J Clin Invest. 85:1990;1844-1852.
27. Laakso M., Edelman S.V., Brechtel G., Baron A.D. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes. 41:1992;1076-1083.
28. Steinberg H.O., Brechtel G., Johnson A., Fineberg N., Baron A.D. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent a novel action of insulin to increase nitric oxide release . J Clin Invest. 94:1994;1172-1179.
29. Baron A.D., Brechtel-Hook G., Johnson A., Cronin J., Leaming R., Steinberg H.O. Effect of perfusion rate on the time course of insulin-mediated skeletal muscle glucose uptake. Am J Physiol. 271:1996;E1067-E1072.
30. Mukherjee R., Davies P.J.A., Crombie D.L., Bischoff E.D., Cesario R.M., Jow L., Hamann L.G., Boehm M.F., Mondon C.E., Nadzan Am, Paterniti J.R. Jr, Heyman R.A. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature. 386:1997;407-410.
31. Ciaraldi T.P., Huber-Knudsen K., Hickman M., Olefsky J.M. Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents. Metabolism. 44:1995;976-982.
32. Park K.S., Ciaraldi T.P., Abrams-Carter L., Mudaliar S., Nikoulina S.E., Henry R.R. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects. J Clin Endocrinol Metab. 83:1998;1636-1643.
33. Park K.S., Ciaraldi T.P., Abrams-Carter L., Mudaliar S., Nikoulina S.E., Henry R.R. PPAR-γ gene expression is elevated in skeletal muscle of obese and type II diabetic subjects. Diabetes. 46:1997;1230-1234.
34. Law R.E., Meehan W.P., Xi X.-P., Graf K., Wuthrich D.A., Coats W., Faxon D., Hsueh W.A. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 98:1996;1897-1905.
35. Hsueh W.A., Law R.E. Cardiovascular risk continuum implications of insulin resistance and diabetes . Am J Med. 105:(suppl 1A):1998;4S-14S.